Pars Planitis Treatment Market Outlook 2025: Opportunities and Emerging Challenges

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Is the Forecasted Market Size of the Pars Planitis Treatment Market by 2029?
 The pars planitis treatment market size has grown strongly in recent years. It will grow from $632.88 billion in 2024 to $683.54 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing awareness of autoimmune eye disorders, rising incidence of uveitis in children, growing access to ophthalmic care, expanding use of immunosuppressants, and growing patient awareness of early intervention.
 
 The pars planitis treatment market size is expected to see strong growth in the next few years. It will grow to $920.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising adoption of biologic therapies, increasing prevalence of autoimmune diseases, growing focus on pediatric eye care, expansion of health insurance coverage, and rising demand for personalized treatment. Major trends in the forecast period include shift toward steroid-sparing therapies, integration of teleophthalmology, development of long-acting implants, use of biosimilars in treatment, and rise in combination therapy.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24649&type=smp
 
 Which Factors Are Driving Growth in the Pars Planitis Treatment Market?
 The increasing prevalence of pars planitis is expected to propel the growth of the pars planitis treatment market going forward. Pars planitis refers to an idiopathic form of intermediate uveitis that primarily causes inflammation in the vitreous and peripheral retina, typically affecting individuals aged 15 to 40. The increasing prevalence of pars planitis is due to growing awareness and improved diagnostic capabilities as advanced imaging tools enable earlier and more accurate detection. Pars planitis treatments help manage pars planitis by reducing ocular inflammation, making them essential for preserving vision and preventing complications. They enhance patient care by offering targeted therapies such as corticosteroids and immunosuppressants, improving long-term eye health and quality of life. For instance, in February 2025, according to a case report published by Mega Journal of Case Reports, a US-based medical journal, intermediate uveitis occurs at a rate of 1.4 to 2 cases per 100,000 people, with the idiopathic form, pars planitis, accounting for 70% of the cases. Therefore, the increasing prevalence of pars planitis is driving the growth of the pars planitis treatment market.
 
 What Are the Key Segments in the Pars Planitis Treatment Market?
 The pars planitis treatment market covered in this report is segmented — 
 
 1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments
 2) By Diagnosis: Blood Tests, X-ray, Magnetic Resonance Imaging (MRI), Other Diagnosis
 3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration 
 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
 5) By End-User: Clinic, Hospital, Other End-Users
 
 Subsegments:
 1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids
 2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
 3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery
 4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy
 5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents
 6) By Other Treatments: Antibiotics, Antivirals, Laser therapy
 
 What Are the Top Trends Expected to Shape the Pars Planitis Treatment Market by 2029?
 Major companies operating in the pars planitis treatment market are focusing on developing innovative solutions, such as bispecific antibodies, to enhance immune modulation, reduce ocular inflammation, and minimize systemic side effects. Bispecific antibodies are engineered proteins designed to bind to two different antigens or targets simultaneously, offering more precise and effective treatment with fewer side effects. For instance, in October 2023, Genentech Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion (RVO), in addition to age-related macular degeneration and diabetic macular edema. Vabysmo is the first bispecific antibody for ophthalmic use that targets both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), addressing inflammation and vascular leakage simultaneously. This innovative mechanism is being explored for use in intermediate uveitis, including pars planitis, where chronic inflammation in the retinal periphery requires durable and targeted intervention.
 
 Who Are the Leading Players in the Pars Planitis Treatment Market?
 Major companies operating in the pars planitis treatment market are Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc., Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Quantum Cryogenics Ltd., Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd., Hologic Inc., Aurobindo Pharma Limited, Santen Pharmaceutical Co. Ltd., CooperSurgical Inc., AtriCure Inc., Alimera Sciences Inc., Clearside Biomedical Inc. 
 
 Get the full pars planitis treatment market report here:
 https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report
 
 What Are the Key Regional Trends in the Pars Planitis Treatment Market?
 North America was the largest region in the pars planitis treatment market in 2024. The regions covered in the pars planitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company